Background: There are still limited data on the efficacy and safety of repeated donations of granulocyte-colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPCs) for allogeneic transplantation.
Study design and methods: Sixty-seven healthy donors undergoing two consecutive mobilizations of PBPCs within a median interval of 5 months (range, 0.1-47 months) were investigated. For both first mobilization (FM) and second mobilization (SM), G-CSF (lenograstim) at 7.5 microg per kg per day was administered.
Results: The nonhematologic side effects were comparable between both mobilizations. A significantly lower yield of CD34+ cells x 10(6) per kg of donor weight was obtained on Day 5 of SM in female (n = 31; FM, 5.0; SM, 3.23; p = 0.008) but not in male (n = 36; FM, 5.96; SM, 5.36; p = 0.24) donors. Multivariate analysis identified a lower CD34+ blood concentration on Day 5 of FM (p < 0.001) as well as female sex (p = 0.015) as independent risk factors for a lower yield of progenitor cells, whereas donor age and body mass index, interval between donations, and schedule of G-CSF application showed no significant impact.
Conclusion: The identified risk factors allow the estimation of the efficacy of a SM in an individual donor before G-CSF administration, thus avoiding distress to both the donor and the recipient.